Merck’s molnupiravir will be ‘complementary, but not a competitor’ to COVID-19 vaccines: analyst
TrustVaccines
via FiercePharma: Vaccines https://ift.tt/2zKtXvv
October 5, 2021 at 09:39AM
Merck’s molnupiravir will be ‘complementary, but not a competitor’ to COVID-19 vaccines: analyst
Welcome to vaccine education 